Evidence map›Paper›PMID 38444528›Full record

ArticleJournal of pharmaceutical policy and practice2024

Survey of community and hospital pharmacist involvement in outpatient chemotherapy using Japanese health information data.

Mari Iwata, Mika Maezawa, Koumi Miyasaka, Sakiko Hirofuji, Takaaki Suzuki, Satoshi Nakao, Hirofumi Tamaki, Nanaka Ichihara, Yuka Nokura, Mayuko Masuta and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mari IwataLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0009-0002-4351-8224
Mika MaezawaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0002-9166-1351
Koumi MiyasakaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Sakiko HirofujiLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Takaaki SuzukiLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Satoshi NakaoLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0001-7413-2637
Hirofumi TamakiLaboratory of Community Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0002-4543-1176
Nanaka IchiharaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Yuka NokuraLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Mayuko MasutaLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Hiroaki UranishiLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Yuri NishibataLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.
Kazuhiro IguchiLaboratory of Community Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0003-1506-9804
Mitsuhiro NakamuraLaboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, Japan.ORCID https://orcid.org/0000-0002-5062-5522

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, information on injectable anticancer drug use and additional fee for enhanced collaboration (AEC) and additional fee for specific drug management guidance 2 (ASD2) claims from the NDB Open Data Japan (NODJ) dataset and the number of patients with cancer according to sex and age from the National Cancer Registry (NCR) dataset were integrated and evaluated to determine the current status and challenges in pharmacist interventions for patients receiving cancer treatment. The NODJ data, including receipt data billed from 2020 to 2021, were obtained from the Ministry of Health, Labour and Welfare website. The use of injectable anticancer drugs decreased relative to the number of cancer patients aged ≥ 75 years compared to those aged < 75 years. Regarding injectable anticancer drug use, the number of AEC claims was similar between men and women, but the number of ASD2 claims was lower in men than in women. The number of times community pharmacists claimed their ASD2 was approximately 5% of the number of times hospital pharmacists claimed their AEC. This study revealed that several patients did not receive sufficient guidance from community pharmacists compared to hospital pharmacists, suggesting a potential insufficiency in the collaboration between the two groups.

Indexed as

additional fee for enhanced collaborationadditional fee for specific drug management guidance 2community pharmacisthospital pharmacistNDB Open Data JapanOutpatient chemotherapy

Identifiers

PMID38444528
PMCPMC10914303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.